Opus advises the shareholders of In2Care on its sale to Envu

Category: Deal Announcement

Opus is delighted to have advised the shareholders of In2Care, a developer of novel mosquito control products, on its sale to Envu.

In2Care has developed a patented technology called InsecTech®. Applied on netting, the long-lasting static-charged coating can bind all types of biocide powders and transfer lethal doses to mosquitoes. This technology is currently available in a professional mosquito station that thousands of pest control operators are already leveraging in the U.S. to control mosquitoes for homeowner customers.

We are very excited to see the development of the partnership between In2Care and Envu as they work to advance healthy environments by preventing the spread of vector-borne diseases. The transaction is expected to close by the year-end 2024.

Opus previously advised Cinven on their acquisition of Envu, previously Bayer Environmental Sciences, in 2022.

For further information please contact: Dr Chris Carlisle, Daniel Barley